During the Q4 conference call, Narasimhan also unveiled an ambitious plan for Novartis' business in China: The Swiss company now aims to double its sales in the country by 2024. In its current earnings report, Novartis started reporting China sales separately; those numbers showed $544 million in Q4 China sales, up 21% at constant currencies, bringing its full-year haul there to about $2.2 billion. RELATED: Novartis, after 5 blockbuster nods in 2019, hopes for 25 more in the coming years To hit its new target, Novartis hopes to move more quickly with regulatory filings on its innovative medicines.